153 related articles for article (PubMed ID: 15069120)
21. Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients.
Camerini A; Rondini M; Garrone O; Valsuani C; Donati S; Siclari O; Sgambato A; Tartarelli G; Vincenti M; Mattiot VP; Porta RP; Puccetti C; Puccinelli P; Amoroso D
Cancer Biol Ther; 2009 Aug; 8(15):1450-5. PubMed ID: 19556864
[TBL] [Abstract][Full Text] [Related]
22. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Scott SM; Brown M; Come SE
Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
[TBL] [Abstract][Full Text] [Related]
23. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
24. Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.
Vergote I; Amant F; Leunen K; Van Gorp T; Berteloot P; Neven P
Int J Gynecol Cancer; 2006; 16 Suppl 2():524-6. PubMed ID: 17010064
[TBL] [Abstract][Full Text] [Related]
25. The history and mechanism of action of fulvestrant.
Carlson RW
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S5-8. PubMed ID: 15865849
[TBL] [Abstract][Full Text] [Related]
26. Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.
Naito A; Carcel-Trullols J; Xie CH; Evans TT; Mizumachi T; Higuchi M
Int J Cancer; 2008 Apr; 122(7):1506-11. PubMed ID: 17990320
[TBL] [Abstract][Full Text] [Related]
27. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen: Dr. Jekyll and Mr. Hyde?
Hayes DF
J Natl Cancer Inst; 2004 Jun; 96(12):895-7. PubMed ID: 15199102
[No Abstract] [Full Text] [Related]
29. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.
Young OE; Renshaw L; Macaskill EJ; White S; Faratian D; Thomas JS; Dixon JM
Eur J Cancer; 2008 Feb; 44(3):391-9. PubMed ID: 18083023
[TBL] [Abstract][Full Text] [Related]
30. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
[TBL] [Abstract][Full Text] [Related]
32. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
34. SERMs: meeting the promise of multifunctional medicines.
Jordan VC
J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
[TBL] [Abstract][Full Text] [Related]
35. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
[TBL] [Abstract][Full Text] [Related]
36. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA
J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513
[TBL] [Abstract][Full Text] [Related]
37. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S; Zelnak A; O'Regan R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
[TBL] [Abstract][Full Text] [Related]
38. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling.
Soulez M; Parker MG
J Mol Endocrinol; 2001 Dec; 27(3):259-74. PubMed ID: 11719280
[TBL] [Abstract][Full Text] [Related]
40. Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
Cappelletti V; Veneroni S; Coradini D; Oriana S; Tomasic G; Younes M; Daidone MG
J Natl Cancer Inst; 2003 Apr; 95(8):629-30. PubMed ID: 12697859
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
